Inhibitor Research Hub

Archives

  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • Translating Mechanistic Insight into Drug Delivery Impact...

    2026-01-20

    This thought-leadership article explores the mechanistic foundations and translational strategies for deploying DMG-PEG2000-NH2—a primary amine-functionalized PEG linker—in advanced liposomal and lipid nanoparticle (LNP) drug delivery. With a focus on the synergy between bioconjugation chemistry, formulation optimization, and clinically relevant outcomes, the article contextualizes APExBIO’s DMG-PEG2000-NH2 within the evolving landscape of translational research. Drawing on both peer-reviewed findings and scenario-driven case studies, we chart a roadmap for researchers seeking to maximize the therapeutic potential of PEGylated delivery systems, including actionable perspectives on siRNA encapsulation, protein conjugation, and next-generation antimycobacterial therapies.

  • Sorafenib: Multikinase Inhibitor Advancing Cancer Biology...

    2026-01-19

    Sorafenib (BAY-43-9006) is a powerful multikinase inhibitor that has redefined experimental workflows in cancer biology, enabling precise interrogation of Raf/MEK/ERK and VEGFR-2 signaling. This in-depth guide details protocols, advanced applications, and troubleshooting strategies, empowering researchers to harness Sorafenib for antiangiogenic and antiproliferative studies across diverse tumor models.

467 records 32/32 page Previous First page 上5页 3132